Drug ID: 1d00000005
Drug Name: Abatacept
Generic Names: Orencia |
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C:
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: Dose is based on body weight and condition of the patient. Weight < 60 kg should receive 500 mg dose, weight 60-100 kg a 750 mg dose and weight >100 kg a 1000 mg dose.
Juvenile Idiopathic Arthritis- Pediatric patients weighing less than 75 kg: receive 10 mg/kg.
Recommended In: This medication is a synthetic protein, prescribed for adult with moderate to severe rheumatoid arthritis including patients who have not responded to DMARDs (disease-modifying anti-rheumatic drugs), and juvenile idiopathic arthritis. It blocks the activity of T-cells, which causes swelling and joint damage in people with arthritis condition.
Directions For Use: It is administered as an injection into the vein (intravenously), or as a solution for subcutaneous (under the skin) injection by a healthcare provider every 2 weeks for the first 3 doses and then every 4 weeks.
Storage: Normally handled and stored by healthcare providers in refrigerator. Do not freeze and keep it away from light.
Dosage Forms: Intravenous injection | Subcutaneous Injecton
Side Effects: Serious- Infection and cancer.
Central Nervous System - Headache and dizziness.
Respiratory - Upper respiratory tract infection and inflammation of nasopharynx.
Gastrointestinal - Nausea, indigestion and severe abdominal pain.
Skin - Rash, red or painful skin, hives.
Miscellaneous- Cough, fever, tiredeness, flu-like symptoms, or warm, swelling of the eyes, face, lips, tongue, or throat, back pain, high blood pressure, indigestion, heartburn, night sweats, urinary tract infection, change in the amount of urine and pain in arms and legs.
Side effects in children - Upper respiratory tract infection, inflammation of nasopharynx, headache, nausea, diarrhea, cough and abdominal pain.
In Case of Overdose: Doses up to 50 mg/kg have been administered intravenously without apparent toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.
Avoid If: Patient may develop with serious infections and tumor. Caution should be exercised in patients with history of lung, nerve diseases (e.g. multiple sclerosis), cancer, Human Immunodeficiency Virus (HIV), tuberculosis (TB), severe combined immunodeficiency syndrome (SCID), cut or open sore, diabetes (especially if you are checking your blood sugar level at home), during pregnancy and breastfeeding.
Avoid vaccination while taking this medication.
Drug Interaction: TNF Antagonists
Concurrent administration of a TNF antagonist with Abatacept has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone. Concurrent therapy with Abatacept and TNF antagonists is not recommended.
Other Biologic RA Therapy
There is insufficient experience to assess the safety and efficacy of Abatacept administered concurrently with other biologic RA therapy, such as anakinra, and therefore such use is not recommended.